Issuance of a 4th tranche of €1.5 million of notes convertible into new shares - Seite 2

Today, DEINOVE has several development programs underway, including the antibiotic candidate   DNV3837, in a Phase II clinical trial in severe gastrointestinal infections with Clostridioides difficile, a real therapeutic challenge. Through its other program AGIR (Antibiotics against Resistant Infectious Germs), supported by Bpifrance, it is also continuing its exploration of biodiversity to supply its portfolio with new molecules. It relies on its own biodiversity and on the one entrusted to it by other specialists in the field.

DEINOVE has also developed and brought to market four particularly innovative active ingredients: two products produced by Deinococcus geothermalis (phytoene and neurosporene), as well as two cell extracts developed in collaboration.

DEINOVE, located in the Euromédecine science park in Montpellier, employs 56 people, mainly researchers, engineers and technicians, and has filed over 350 patent applications internationally. It is listed on EURONEXT GROWTH (ALDEI – code ISIN FR0010879056).

CONTACTS

Investors Mario Alcaraz Chief Financial and Administrative Officer Phone: [phone] [e-mail]   Media                                                                                                       ALIZE RP - Caroline Carmagnol Phone: [phone] [e-mail]

 

---

¹ Press release dated July 9, 2019 available on the Company's website (http://www.deinove.com/en/news/all-press-releases/issuance-notes-convertible-new-shares-maximum-amount-eu15m-issuance-first-eu22-million-tranche)

² Press release dated April 3, 2020 available on the Company's website
(http://www.deinove.com/en/news/all-press-releases/issuance-2nd-tranch- ...)

 

 

Attachment

• PR in English